WHILE THE WHO STOPS PROMOTING VACCINATIONS, A HEALTH EXPERT EMPHASISES THE "FREEDOM OF CHOICE" FOR COVID BOOSTERS.

Great news!>>>>

Great news! A vaccine has been approved by the US Food and Drug Administration (FDA) to protect against the respiratory syncytial virus (RSV), and it's expected to benefit thousands of people. 

This is the first time a vaccine for RSV has been approved, and it's a huge milestone that's taken decades to achieve. The approval was granted on May 3 and is specifically for individuals over the age of 60. The RSV vaccination should be approved by the US Centres for Disease Control and Prevention and become accessible in US pharmacies and clinics by the fall. This is fantastic news since, although RSV is frequently mild and mimics the common cold, it may be devastating for elderly people, especially those with underlying medical conditions. Surprisingly, over 14,000 people over 65 die with RSV each year in the US, and tens of thousands more are hospitalised. 

Infants are also in danger, and severe infections are thought to be a factor in the 100 to 500 baby fatalities that occur annually in the US; the figure is much greater in underdeveloped countries. As a result, attempts to develop an RSV vaccine have been futile for many years until recently. The Arexvy, Today marks a turning point in our effort to reduce the significant burden of RSV,"  Tony Wood, the Chief Scientific Officer at GSK in the UK. "Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries."Development of the vaccine was spurred on by a closer analysis of the protein that RSV uses to fuse with and infect cells, and from this.

A similar technique was also used to develop COVID vaccines in recent years. Approval for the vaccine was granted after a trial of almost 25,000 participants, with half receiving Arexvy and the other half receiving placebos. In people aged 60 or over, Arexvy reduced the risk of getting lower respiratory tract disease through RSV by 82.6 per cent and of developing the severe disease by 94.1 per cent. The New England Journal of Medicine reported the vaccination trials' findings earlier this year. The head of the FDA's Centre for Biologics Evaluation and Research, Peter Marks, claims that older persons with underlying medical issues including heart or lung disease or compromised immune systems are more vulnerable to developing severe RSV-related illness. Therefore, the FDA's clearance of the first RSV vaccination represents an important public health achievement in the fight against serious illnesses.

This vaccine, together with the next ones, should considerably lower the projected $1 billion in hospital expenditures associated with RSV each year in the US. RSV vaccinations are also being developed for pregnant women and other groups. According to GSK, work has already begun. T efforts to obtain authorization to give the vaccine to those 50 to 59 years old and it is anticipated that it will soon be approved in other countries, which will reduce the number of RSV cases.

>>click here>>https://fe13dfbljbtz2287pnrgq5psc2.hop.clickbank.net 

An important advance, in the opinion of immunologist Barney Graham of the Morehouse School of Medicine in Atlanta, is the availability of RSV illness prevention methods. Great news! A vaccine has been approved by the US Food and Drug Administration (FDA) to protect against the respiratory syncytial virus (RSV), and it's expected to benefit thousands of people. This is the first time a vaccine for RSV has been approved, and it's a huge milestone that's taken decades to achieve. The approval was granted on May 3 and is specifically for individuals over the age of 60. The RSV vaccination should be approved by the US Centres for Disease Control and Prevention and become accessible in US pharmacies and clinics by the fall. This is fantastic news since, although RSV is frequently mild and mimics the common cold, it may be devastating for elderly people, especially those with underlying medical conditions. Surprisingly, over 14,000 people over 65 die with RSV each year in the US, and tens of thousands more are hospitalised. Infants are also in danger, and severe infections are thought to be a factor in the 100 to 500 baby fatalities that occur annually in the US; the figure is much greater in underdeveloped countries. As a result, attempts to develop an RSV vaccine have been futile for many years until recently. The Arexvy, Today marks a turning point in our effort to reduce the significant burden of RSV,"  Tony Wood, the Chief Scientific Officer at GSK in the UK. "Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries."Development of the vaccine was spurred on by a closer analysis of the protein that RSV uses to fuse with and infect cells, and from this. A similar technique was also used to develop COVID vaccines in recent years. Approval for the vaccine was granted after a trial of almost 25,000 participants, with half receiving Arexvy and the other half receiving placebos. In people aged 60 or over, Arexvy reduced the risk of getting lower respiratory tract disease through RSV by 82.6 per cent and of developing the severe disease by 94.1 per cent. The New England Journal of Medicine reported the vaccination trials' findings earlier this year. The head of the FDA's Centre for Biologics Evaluation and Research, Peter Marks, claims that older persons with underlying medical issues including heart or lung disease or compromised immune systems are more vulnerable to developing severe RSV-related illness. Therefore, the FDA's clearance of the first RSV vaccination represents an important public health achievement in the fight against serious illnesses.

vaccine has been approved by the US Food and Drug Administration (FDA) to

protect against the respiratory syncytial virus (RSV), and it's expected to benefit thousands of people. This is the first time a vaccine for RSV has been approved, and it's a huge milestone that's taken decades to achieve. The approval was granted on May 3 and is specifically for individuals over the age of 60. The RSV vaccination should be approved by the US Centres for Disease Control and Prevention and become accessible in US pharmacies and clinics by the fall. This is fantastic news since, although RSV is frequently mild and mimics the common cold, it may be devastating for elderly people, especially those with underlying medical conditions. Surprisingly, over 14,000 people over 65 die with RSV each year in the US, and tens of thousands more are hospitalised. Infants are also in danger, and severe infections are thought to be a factor in the 100 to 500 baby fatalities that occur annually in the US; the figure is much greater in underdeveloped countries. As a result, attempts to develop an RSV vaccine have been futile for many years until recently. A similar technique was also used to develop COVID vaccines in recent years. Approval for the vaccine was granted after a trial of almost 25,000 participants, with half receiving Arexvy and the other half receiving placebos. In people aged 60 or over, Arexvy reduced the risk of getting lower respiratory tract disease through RSV by 82.6 per cent and of developing the severe disease by 94.1 per cent. The New England Journal of Medicine reported the vaccination trials' findings earlier this year. The head of the FDA's Centre for Biologics Evaluation and Research, Peter Marks, claims that older persons with underlying medical issues including heart or lung disease or compromised immune systems are more vulnerable to developing severe RSV-related illness. Therefore, the FDA's clearance of the first RSV vaccination represents an important public health achievement in the fight against serious illnesses.

click here>>https://fbabdlpeqd1w2038r662od1w44.hop.clickbank.net

This vaccine, together with the next ones, should considerably lower the projected $1 billion in hospital expenditures associated with RSV each year in the US. RSV vaccinations are also being developed for pregnant women and other groups. According to GSK, work has already begun. T efforts to obtain authorization to give the vaccine to those 50 to 59 years old and it is anticipated that it will soon be approved in other countries, which will reduce the number of RSV cases. An important advance, in the opinion of immunologist Barney Graham of the Morehouse School of Medicine in Atlanta, is the availability of RSV illness prevention methods.